• Deltex Medical Group Plc (DEMG) has announced its unaudited interim results for the six months ended 30 June 2019.
  • The company’s revenues in the reported period declined to £2.0 million from £2.3 million reported in H1 FY18.
  • The company reported 35 per cent reduction in overhead costs (excluding exceptional items) to £1.7 million as compared to £2.7 million in H1 FY18.
  • The loss for the reported period reduced to £0.3 million from a loss of £1.2 million reported in H1 FY18.
  • On 23rd September 2019, at the time of writing, GMT 08:09 AM, DEMG shares were trading at GBX 1.35, up by 0.025 points or 1.89% against the previous day closing price.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK